ImmunogenX

Latiglutenase Therapy

Latiglutenase is a mixture of recombinant proteases that degrade gluten proteins in the stomach rendering them physiologically inactive. The drug has been extensively studied in Phase 2a and 2b clinical trials where it has demonstrated protection of intestinal mucosal injury and symptomatic improvement in CD patients.

CypCel Diagnostics

For disease management we are running a new clinical study following a proof of concept study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective diagnostics.

Gluten Proteomics

For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

Latest News

ImmunogenX (50 Best Companies to Watch 2018: May 2018)

Dr. Jennifer Sealey Voyksner and Dr. Jack Syage speak at National Conference (Celiac Disease Foundation: May 5th, 2018)

The Dilemma of the Gluten-Free Diet (Wall Street Journal: April 16th, 2018)

When Going Gluten-Free Is Not Enough: New Tests Detect Hidden Exposure (NPR: April 3rd, 2018)

Gluten-Free Diet May Still Allow Harmful Levels of Exposure (Reuters: March 21st, 2018)